Grace Therapeutics, Inc.
GRCEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Grace Therapeutics, Inc. (GRCE) is listed under Biotechnology. The company carries a $40.6M market cap, placing it firmly in the micro-cap category. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage.
Market Cap
$40.6M
Beta
0.33
P/E (TTM)
—
P/E (Fwd)
-4.24
EPS (TTM)
$-1.17
EPS (Fwd)
$-0.46
ROE
-36.2%
ROA
-10.8%
Cash
$13.8M
Total Debt
$0
Free CF
-$7.0M
52W Change
-38.7%
Annual Financials
Cash vs Debt
Where GRCE stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, GRCE finished 28.41% below its 150-day moving average ($2.64) and 35.27% below its 200-day moving average ($2.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRCE overbought or oversold?
At the October 15, 2026 close, GRCE's RSI(14) was 26.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Grace Therapeutics, Inc. reports $13.8M in cash and $0 in total debt. Free cash flow is running at -$7.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -36.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.33 suggests GRCE is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing GRCE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.